SunTrust analyst Peter Lawson initiated Incyte with a Buy and $105 price target saying the company is transitioning into a profitable large cap biotech with a US/EU salesforce, and moving from rarer indications to more prevalent inflammatory and oncology indications. Lawson expects upside will come from the pipeline of targeted medicine and oncology assets including epacadostat. The pullback in the stock this year was due to Jakafi failing in treating solid tumor. However, with upcoming immunooncology data and approval of a second internally developed drug, he believes it's time to own the stock.